Drugs / Proximod
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06361199 | Dec 2021 → Feb 2022 | rheumatoid arthritis | Longevity Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06361186 | Sep → Nov 2017 | rheumatoid arthritis | Longevity Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07335952 | Sep 2024 → Oct 2025 | rheumatoid arthritis | Peking University People's Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Proximod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06361186 ↗ |
| Action | Activate | “selective agonist” PMID 39454617 ↗ Oct 2024 |
| Route | Oral | “oral administration for 28 days” NCT06361186 ↗ |
| Target | S1PR1 | “selective agonist of sphingosine-1-phosphate receptor-1 (S1PR1)” PMID 39454617 ↗ Oct 2024 |